Risk of hormone replacement therapy in stroke patients

Journal of Clinical Pharmacy and Therapeutics

Volumn 25, Issue 4, 2000, Pages 239-241

  Damczyk, ^a   Gardner, ^a,b  

^a DALHOUSIE UNIVERSITY   (Canada)

^b QUEEN ELIZABETH II HEALTH SCIENCES CENTRE   (Canada)

Author keywords

Hormone replacement therapy; Stroke

Indexed keywords

ACETYLSALICYLIC ACID; ESTROGEN; GESTAGEN; ORAL CONTRACEPTIVE AGENT;

ADULT; ARTICLE; BREAST CANCER; CASE REPORT; DRUG INDICATION; ESTROGEN DEFICIENCY; FEMALE; HORMONE SUBSTITUTION; HUMAN; HUMAN CELL; HUMAN TISSUE; RISK BENEFIT ANALYSIS; RISK FACTOR; STROKE; THROMBOEMBOLISM; UTERUS CANCER;

CEREBROVASCULAR ACCIDENT; EPIDEMIOLOGIC STUDIES; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; MIDDLE AGED; PREMENOPAUSE; RISK ASSESSMENT;

EID: 0033802284     PISSN: 02694727     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2710.2000.00280.x     Document Type: Article

References (11)

1. Hormone replacement therapy
2. The pill: Combined oral contraceptives
3. Ischemic stroke and use of estrogen and estrogen/progesterone as hormone replacement therapy
4. Hormone replacement therapy and risk of non-fatal stroke
5. Hormone replacement therapy and the risk of stroke
6. Estrogen replacement therapy and stroke
7. Association between increased estrogen status and increased fibrinolytic potential in the Framingham offspring study
8. Effects of hormone replacement therapy on the circadian pattern of atherothrombotic risk factors
9. Effects of oral and transdermal estrogen/progesterone regimens on blood coagulation and fibrinolysis in postmenopausal women